Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

World journal of gastroenterology - 28 Oct 2009

Schulz Christoph, Heinemann Volker, Schalhorn Andreas, Moosmann Nikolas, Zwingers Thomas, Boeck Stefan, Giessen Clemens, Stemmler Hans-Joachim

Abstract excerpt

AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC) receiving a low-dose weekly irinotecan chemotherapeutic regimen. METHODS: Genotypes were retrospectively evaluated by gene scan analysis on the ABI 310 sequencer of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Diarrhea

Share to Disease Progression

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 19859999
DOI: 10.3748/wjg.15.5058
PMCID: PMC2768885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.PMID 19859999Read ↗

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.Semantic proximity Read ↗

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.Semantic proximity Read ↗

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerSemantic proximity Read ↗

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.Semantic proximity Read ↗

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.Semantic proximity Read ↗

The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Semantic proximity Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.